论文部分内容阅读
目的:探讨校正后的流式细胞术原始细胞计数在骨髓增生异常综合征(MDS)分型诊断中的应用价值。方法:采用流式细胞术多重逻辑设门技术计算73例MDS患者骨髓中CD16dim/-粒细胞和CD34+细胞比例,根据CD16dim/-粒细胞比例对骨髓外周血稀释进行校正,再计算骨髓中校正后的CD34+细胞数;采用校正后的CD34+细胞数进行MDS分型诊断,并与形态学分型诊断进行比较。结果:对照组和MDS组骨髓CD16dim/-粒细胞所占的比例分别为(50.33±17.52)%和(52.35±27.48)%(P>0.05),形态学原始细胞数分别为(0.43±0.64)%和(2.48±3.67)%(P<0.01)。MDS组校正前、后CD34+细胞数分别为(1.86±2.53)%和(3.24±4.02)%(P<0.01),前者明显低于形态学原始细胞数(P<0.05),后者明显高于形态学原始细胞数(P<0.05),但63/73例粒细胞CD16表达水平正常的MDS患者骨髓校正后的CD34+细胞数与形态学原始细胞数并无明显差异,二者用于MDS分型诊断的符合率达96.8%。结论:骨髓中CD16dim/-粒细胞数可用于骨髓外周血稀释的校正;校正后的骨髓CD34+细胞数可用于粒细胞CD16表达正常的MDS患者的分型诊断。
Objective: To investigate the value of calibrated flow cytometry blast cell count in the diagnosis of myelodysplastic syndrome (MDS). Methods: The proportion of CD16dim / - granulocytes and CD34 + cells in bone marrow of 73 patients with MDS was calculated by flow cytometry multiple logic gating technique. The dilution of bone marrow was corrected according to the proportion of CD16dim / The number of CD34 + cells was counted. The corrected CD34 + cells were used to diagnose MDS and compared with the morphological diagnosis. Results: The percentage of CD16dim / - granulocytes in control group and MDS group was (50.33 ± 17.52)% and (52.35 ± 27.48)%, respectively. The number of morphologically primitive cells was (0.43 ± 0.64)% % And (2.48 ± 3.67)% (P <0.01). The number of CD34 + cells in the MDS group before and after the correction were (1.86 ± 2.53)% and (3.24 ± 4.02)%, respectively (P <0.01), the former was significantly lower than the number of morphologically primitive cells (P <0.05) (P <0.05). However, there was no significant difference between the number of CD34 + cells and the number of morphologically primitive cells in MDS patients with normal expression of CD16 in 63/73 granulocytes, both of which were used for MDS typing Diagnostic compliance rate of 96.8%. CONCLUSION: The number of CD16dim / - granulocytes in bone marrow can be used for the correction of bone marrow peripheral blood dilution. The corrected number of CD34 + cells in bone marrow can be used to diagnose the type of MDS with normal CD16 expression.